Eli Lilly plans to begin advertising weight-loss drug Zepbound
Eli Lilly ( LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite investor and industry recognition of the branded GLP-1 drug, "unaided awareness of Zepbound ... is actually not very high," CEO David Ricks said on an earnings call Wednesday morning.
Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not ...
Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
The drugmaker has received approval from the Hong Kong government to sell its tirzepatide injections — branded as Mounjaro — ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback